Evercore ISI Group analyst Josh Schimmer downgrades BELLUS Health (NASDAQ:BLU) from Outperform to In-Line and lowers the price target from $24 to $14.75.
Evercore ISI Group Downgrades BELLUS Health to In-Line, Lowers Price Target to $14.75
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.